Introduction

For many patients diagnosed with papillary thyroid cancer, the first surgery is not always the only one. A significant number of people who have a lobectomy, where only part of the thyroid is removed, find themselves needing a second operation just weeks later to remove the rest of the gland. This second surgery is called a completion thyroidectomy, and for someone who has already been through one operation, hearing that they need another can be genuinely devastating.

In our previous article, we introduced Thyroid GuidePx® and how it helps classify papillary thyroid cancer by its underlying biology. Here, we want to focus on one of the most meaningful ways this test can change a patient’s experience: helping avoid that second surgery altogether.

Why Does a Second Surgery Happen?

When someone is diagnosed with papillary thyroid cancer, one of the earliest decisions is how much of the thyroid to remove. For smaller tumors that have not spread to nearby lymph nodes, a lobectomy is often a reasonable starting point. It is less invasive than removing the entire gland, and for many patients it sounds like the gentler, more proportionate choice.

The difficulty is that some of the most important information about how aggressive a cancer is simply does not become clear until after the surgery. Once the removed tissue is examined closely in a laboratory, features are sometimes found that suggest a higher risk of recurrence than anyone expected going in. When that happens, doctors may recommend removing the remaining half of the thyroid to make sure the cancer is fully addressed.

This two-step sequence, a lobectomy followed by a completion thyroidectomy, happens more often than most patients realize. Research shows that in a significant proportion of patients initially considered good candidates for a lobectomy, higher risk features only surface afterward in the final pathology report^1-6.

Why Two Surgeries Is So Hard

Going through one cancer surgery is already a lot. Being told that a second one is necessary, often within just a few weeks of the first, adds a whole new layer of physical and emotional strain on top of an already difficult experience.

What surprises many patients is that the second surgery is not necessarily simpler or safer just because it is smaller in scope. A completion thyroidectomy is technically more challenging than an initial total thyroidectomy, because the surgeon is now working in an area that has already begun to heal from the first operation. Completion thyroidectomy carries similar complication rates to an initial total thyroidectomy, including temporary vocal cord weakness in roughly 3 to 5% of patients, temporary low calcium levels in approximately 8 to 9% of patients, and longer-term low calcium levels in up to about 1.5% of patients^7-8.

And beyond the physical risks, there is the emotional weight of having to prepare for, recover from, and process two separate surgeries in quick succession, often while still coming to terms with the original diagnosis.

How Thyroid GuidePx® Helps

This is exactly the problem Thyroid GuidePx® was designed to address. Rather than waiting for surgical pathology to reveal how aggressive a cancer is, Thyroid GuidePx® analyses the biology of the tumor before that decision is even made. It gives patients and their surgical team meaningful information about recurrence risk upfront, at the moment when it can actually shape the treatment plan.

For patients whose tumor is classified as low risk, that information provides real confidence that a lobectomy alone is likely to be the right call. There is no longer a need to proceed under uncertainty and then wait anxiously to find out if a second surgery will be required.

For patients whose tumor turns out to be higher risk, the value is just as significant. Instead of discovering this after a first surgery, a more complete approach can be planned and discussed from the very beginning. The situation where a patient has a lobectomy only to be told weeks later that more surgery is needed becomes much less likely.

In both cases, what Thyroid GuidePx® offers is clarity at the right moment, before a decision is made rather than after.

What This Means for You

If you have been diagnosed with papillary thyroid cancer and are facing decisions about surgery, it is worth asking your care team whether molecular testing like Thyroid GuidePx® is appropriate for your situation. It will not change your diagnosis, but it can meaningfully change the path you take to treat it and potentially spare you from the experience of going through two surgeries when one would have been enough.

Conclusion

A cancer diagnosis already asks a great deal of patients. The prospect of an unexpected second surgery should not have to be part of that. Thyroid GuidePx® offers a way to bring clarity earlier in the process, helping more patients move through treatment with a single, well-informed plan from the start.

If you would like to learn more about Thyroid GuidePx® and whether it may be relevant to your care, visit qualisuredx.com.

References

1. Cheng SP, Chien MN, Wang TY, Lee JJ, Lee CC, Liu CL. Reconsideration of tumor size threshold for total thyroidectomy in differentiated thyroid cancer. Surgery. Sep 2018;164(3):504–510. doi:10.1016/j.surg.2018.04.019
2. Dhir M, McCoy KL, Ohori NP, et al. Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. Surgery. Jan 2018;163(1):81-87. doi:10.1016/j.surg.2017.04.029
3. Lang BH, Shek TW, Wan KY. The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4 cm: Implications for completion thyroidectomy following lobectomy. Clin Endocrinol (Oxf). Feb 2017;86(2):236-242. doi:10.1111/cen.13165
4. Kluijfhout WP, Pasternak JD, Lim J, et al. Frequency of high-risk characteristics requiring total thyroidectomy for 1-4 cm well differentiated thyroid cancer. Thyroid. Jun 2016;26(6):820-824. doi:10.1089/thy.2015.0495
5. Murthy SP, Balasubramanian D, Subramaniam N, et al. Prevalence of adverse pathological features in 1 to 4 cm low-risk differentiated thyroid carcinoma. Head Neck. Jun 2018;40(6):1214-1218. doi:10.1002/hed.25099
6. Craig SJ, Bysice AM, Nakoneshny SC, Pasieka JL, Chandarana SP. The identification of intraoperative risk factors can reduce, but not exclude, the need for completion thyroidectomy in low-risk papillary thyroid cancer patients. Thyroid. Feb 2020;30(2):222-228. doi:10.1089/thy.2019.0274
7. Bin Saleem R, Bin Saleem M, Bin Saleem N. Impact of completion thyroidectomy timing on post-operative complications: A systematic review and meta-analysis. Gland Surg. Oct 2018;7(5):458-465. doi:10.21037/gs.2018.09.03
8. Canu GL, Medas F, Cappellacci F, et al. Risk of complications in patients undergoing completion thyroidectomy after hemithyroidectomy for thyroid nodule with indeterminate cytology: An Italian Multicentre Retrospective Study. Cancers (Basel). May 17, 2022;14(10). doi:10.3390/cancers14102472